Expression, purification, and characterization of human factor XIII in Saccharomyces cerevisiae - PubMed

Affiliations

• PMID: 2184890
• DOI: 10.1021/bi00459a028

Expression, purification, and characterization of human factor XIII in Saccharomyces cerevisiae

P D Bishop et al. Biochemistry. 1990.

Abstract

Factor XIII is the terminal enzyme of the clotting cascade. A cDNA sequence encoding human placental factor XIII was expressed in Saccharomyces cerevisiae with the yeast ADH2-4c promoter. Expression levels were a strong function of the noncoding flanking DNA content of the construction. When the terminal 3'-flanking noncoding DNA was removed, expression increased approximately 50-fold. The protein was produced in quantity by high-yield fermentation and purified to homogeneity. The recombinant protein was cleaved by thrombin at the same activation site as purified human placental FXIII and exhibited 100% enzymatic activity. At high thrombin concentrations rFXIIIa was cleaved into inactive 54- and 25-kDa polypeptides. The identity of these cleavage sites and the blocked N-terminus to that of the human protein was revealed by amino acid microsequencing. A time course of thrombin activation was performed and the relative distribution of the thrombin-cleaved subunits to the uncleaved zymogen subunits determined; the results were consistent with the half of the sites catalytic model for transglutaminase activity proposed by Chung et al. (Chung, S. I., Lewis, M. S., & Folk, J. E. (1974) J. Biol. Chem. 249, 940-950, 1974) and Hornyak et al. (Hornyak, T. J., Bishop, P. D., & Shafer, J. A. (1989) Biochemistry 28, 7326-7332). Equilibrium and velocity sedimentation analysis indicated that rFXIII exists as a 166-kDa nondissociating dimer that behaves as a compact particle of 8.02 S. Thus, all of the properties of rFXIII thus far examined are consistent with those reported for human platelet and placental FXIII.(ABSTRACT TRUNCATED AT 250 WORDS)

Similar articles

• Purification and characterization of recombinant human coagulant factor XIII A-chains expressed in E. coli.

  Lai TS, Santiago MA, Achyuthan KE, Greenberg CS. Lai TS, et al. Protein Expr Purif. 1994 Apr;5(2):125-32. doi: 10.1006/prep.1994.1019. Protein Expr Purif. 1994. PMID: 7914444

• Purification and properties of factor XIII from human placenta.

  De Backer-Royer C, Traoré F, Meunier JC. De Backer-Royer C, et al. Int J Biochem. 1992;24(1):91-7. doi: 10.1016/0020-711x(92)90234-r. Int J Biochem. 1992. PMID: 1349868

• Analysis of factor XIII substrate specificity using recombinant human factor XIII and tissue transglutaminase chimeras.

  Hettasch JM, Peoples KA, Greenberg CS. Hettasch JM, et al. J Biol Chem. 1997 Oct 3;272(40):25149-56. doi: 10.1074/jbc.272.40.25149. J Biol Chem. 1997. PMID: 9312126

• Factor XIII: congenital deficiency factor XIII, acquired deficiency, factor XIII A-subunit, and factor XIII B-subunit.

  Tahlan A, Ahluwalia J. Tahlan A, et al. Arch Pathol Lab Med. 2014 Feb;138(2):278-81. doi: 10.5858/arpa.2012-0639-RS. Arch Pathol Lab Med. 2014. PMID: 24476525 Review.

• Novel aspects of blood coagulation factor XIII. I. Structure, distribution, activation, and function.

  Muszbek L, Adány R, Mikkola H. Muszbek L, et al. Crit Rev Clin Lab Sci. 1996;33(5):357-421. doi: 10.3109/10408369609084691. Crit Rev Clin Lab Sci. 1996. PMID: 8922891 Review.

Cited by

• Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta.

  Nunes I, Gleizes PE, Metz CN, Rifkin DB. Nunes I, et al. J Cell Biol. 1997 Mar 10;136(5):1151-63. doi: 10.1083/jcb.136.5.1151. J Cell Biol. 1997. PMID: 9060478 Free PMC article.

• Recombinant factor XIII improves established experimental colitis in rats.

  D'Argenio G, Grossman A, Cosenza V, Valle ND, Mazzacca G, Bishop PD. D'Argenio G, et al. Dig Dis Sci. 2000 May;45(5):987-97. doi: 10.1023/a:1005541512152. Dig Dis Sci. 2000. PMID: 10795765

• A non-reactive glutamine residue of alpha2-antiplasmin promotes interactions with the factor XIII active site region.

  Cleary DB, Doiphode PG, Sabo TM, Maurer MC. Cleary DB, et al. J Thromb Haemost. 2009 Nov;7(11):1947-9. doi: 10.1111/j.1538-7836.2009.03583.x. Epub 2009 Aug 19. J Thromb Haemost. 2009. PMID: 19691486 Free PMC article. No abstract available.

• Activation of factor XIII is accompanied by a change in oligomerization state.

  Anokhin BA, Stribinskis V, Dean WL, Maurer MC. Anokhin BA, et al. FEBS J. 2017 Nov;284(22):3849-3861. doi: 10.1111/febs.14272. Epub 2017 Oct 3. FEBS J. 2017. PMID: 28915348 Free PMC article.

• Impaired dimer assembly and decreased stability of naturally recurring R260C mutant A subunit for coagulation factor XIII.

  Maeda S, Zhang WG, Souri M, Yee VC, Ichinose A. Maeda S, et al. J Biochem. 2012 Nov;152(5):471-8. doi: 10.1093/jb/mvs088. Epub 2012 Aug 25. J Biochem. 2012. PMID: 22923741 Free PMC article.

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database